PL2539366T3 - Przeciwciała wiążące protofibryle i ich zastosowanie w sposobach terapeutycznych i diagnostycznych w chorobie parkinsona, otępieniu z ciałami lewy'ego i innych alfa-synukleinopatiach - Google Patents
Przeciwciała wiążące protofibryle i ich zastosowanie w sposobach terapeutycznych i diagnostycznych w chorobie parkinsona, otępieniu z ciałami lewy'ego i innych alfa-synukleinopatiachInfo
- Publication number
- PL2539366T3 PL2539366T3 PL11713058T PL11713058T PL2539366T3 PL 2539366 T3 PL2539366 T3 PL 2539366T3 PL 11713058 T PL11713058 T PL 11713058T PL 11713058 T PL11713058 T PL 11713058T PL 2539366 T3 PL2539366 T3 PL 2539366T3
- Authority
- PL
- Poland
- Prior art keywords
- protofibril
- synucleinopathies
- dementia
- parkinson
- alpha
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
- A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
- A61K51/04—Organic compounds
- A61K51/08—Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
- A61K51/10—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody
- A61K51/1018—Antibodies or immunoglobulins; Fragments thereof, the carrier being an antibody, an immunoglobulin or a fragment thereof, e.g. a camelised human single domain antibody or the Fc fragment of an antibody against material from animals or humans
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/0004—Screening or testing of compounds for diagnosis of disorders, assessment of conditions, e.g. renal clearance, gastric emptying, testing for diabetes, allergy, rheuma, pancreas functions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
- G01N33/54306—Solid-phase reaction mechanisms
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
- G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
- G01N2800/2814—Dementia; Cognitive disorders
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
- G01N2800/2814—Dementia; Cognitive disorders
- G01N2800/2821—Alzheimer
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
- G01N2800/2835—Movement disorders, e.g. Parkinson, Huntington, Tourette
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/30—Psychoses; Psychiatry
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/30—Psychoses; Psychiatry
- G01N2800/302—Schizophrenia
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/38—Pediatrics
- G01N2800/385—Congenital anomalies
- G01N2800/387—Down syndrome; Trisomy 18; Trisomy 13
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Biomedical Technology (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Urology & Nephrology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Hematology (AREA)
- Biochemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Pathology (AREA)
- Physics & Mathematics (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Analytical Chemistry (AREA)
- Biotechnology (AREA)
- Cell Biology (AREA)
- Food Science & Technology (AREA)
- General Physics & Mathematics (AREA)
- Microbiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Epidemiology (AREA)
- Psychiatry (AREA)
- Diabetes (AREA)
- Optics & Photonics (AREA)
- Endocrinology (AREA)
- Gastroenterology & Hepatology (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US30863810P | 2010-02-26 | 2010-02-26 | |
| US40626010P | 2010-10-25 | 2010-10-25 | |
| EP11713058.3A EP2539366B1 (en) | 2010-02-26 | 2011-02-25 | Protofibril-binding antibodies and their use in therapeutic and diagnostic methods for parkinson's disease, dementia with lewy bodies and other alpha-synucleinopathies |
| PCT/IB2011/050826 WO2011104696A1 (en) | 2010-02-26 | 2011-02-25 | Protofibril-binding antibodies and their use in therapeutic and diagnostic methods for parkinson's disease, dementia with lewy bodies and other alpha-synucleinopathies |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| PL2539366T3 true PL2539366T3 (pl) | 2018-06-29 |
Family
ID=44227520
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PL11713058T PL2539366T3 (pl) | 2010-02-26 | 2011-02-25 | Przeciwciała wiążące protofibryle i ich zastosowanie w sposobach terapeutycznych i diagnostycznych w chorobie parkinsona, otępieniu z ciałami lewy'ego i innych alfa-synukleinopatiach |
Country Status (19)
| Country | Link |
|---|---|
| US (4) | US8632776B2 (pl) |
| EP (1) | EP2539366B1 (pl) |
| JP (1) | JP5894939B2 (pl) |
| CN (3) | CN102869680B (pl) |
| AU (1) | AU2011219414B2 (pl) |
| CA (1) | CA2789963C (pl) |
| CY (1) | CY1120014T1 (pl) |
| DK (1) | DK2539366T3 (pl) |
| ES (1) | ES2661925T3 (pl) |
| HR (1) | HRP20180230T8 (pl) |
| HU (1) | HUE038313T2 (pl) |
| LT (1) | LT2539366T (pl) |
| NO (1) | NO2539366T3 (pl) |
| PL (1) | PL2539366T3 (pl) |
| PT (1) | PT2539366T (pl) |
| RS (1) | RS57029B1 (pl) |
| RU (1) | RU2555526C2 (pl) |
| SI (1) | SI2539366T1 (pl) |
| WO (1) | WO2011104696A1 (pl) |
Families Citing this family (61)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PT2282758T (pt) | 2008-04-29 | 2019-02-12 | Bioarctic Ab | Anticorpos e vacinas para uso em métodos terapêuticos e diagnósticos para perturbações relacionadas com a alfa-sinucleína |
| JP5894939B2 (ja) | 2010-02-26 | 2016-03-30 | バイオアークティック ニューロサイエンス アーベー | プロトフィブリル結合抗体ならびにパーキンソン病、レビー小体型認知症および他のα−シヌクレイノパチーの治療および診断方法におけるこれらの使用 |
| PL3604339T3 (pl) | 2011-01-14 | 2021-12-27 | The Regents Of The University Of California | Terapeutyczne przeciwciała przeciwko białku ror-1 i sposoby ich zastosowania |
| BR112014017814A8 (pt) * | 2012-01-20 | 2017-07-11 | Genzyme Corp | Anticorpos anti-cxcr3 |
| US9534044B2 (en) | 2013-02-28 | 2017-01-03 | United Arab Emirates University | Alpha-synuclein antibodies and uses thereof |
| MX2016005631A (es) | 2013-11-21 | 2016-07-14 | Hoffmann La Roche | Anticuerpos anti-alfa-sinucleina y metodos de uso. |
| CA2951990C (en) * | 2014-07-10 | 2023-08-22 | Bioarctic Neuroscience Ab | Improved a.beta. protofibril binding antibodies |
| WO2016040905A1 (en) * | 2014-09-11 | 2016-03-17 | Board Of Regents Of The University Of Texas System | Detection of misfolded alpha synuclein protein |
| JP2017536102A (ja) | 2014-10-16 | 2017-12-07 | ジェネンテック， インコーポレイテッド | 抗アルファ−シヌクレイン抗体及び使用方法 |
| CA2977646A1 (en) * | 2015-02-24 | 2016-09-01 | Rpeptide, Llc | Anti-amyloid-beta antibodies |
| EP3091087A1 (en) | 2015-05-08 | 2016-11-09 | Fundació Institut d'Investigació en Ciències de la Salut Germans Trias i Pujol | Method for in vitro diagnosis of synucleinopathies using alpha-synuclein gene transcripts |
| GB201512203D0 (en) | 2015-07-13 | 2015-08-19 | Lundbeck & Co As H | Agents,uses and methods |
| EP3325506A1 (en) | 2015-07-21 | 2018-05-30 | BioArctic AB | Method for treatment of traumatic brain injury targeting aggregated peptides |
| US10772969B2 (en) | 2015-11-09 | 2020-09-15 | The University Of British Columbia | N-terminal epitopes in amyloid beta and conformationally-selective antibodies thereto |
| WO2017079833A1 (en) | 2015-11-09 | 2017-05-18 | The University Of British Columbia | Epitopes in amyloid beta mid-region and conformationally-selective antibodies thereto |
| WO2017079835A1 (en) | 2015-11-09 | 2017-05-18 | The University Of British Columbia | Amyloid beta epitopes and antibodies thereto |
| IL261188B (en) | 2016-03-04 | 2022-08-01 | Jn Biosciences Llc | An anti-tigit antibody that binds to the tigit polypeptide on one or more amino acid residues |
| EP4000632A1 (en) * | 2016-06-02 | 2022-05-25 | MedImmune Limited | Antibodies to alpha-synuclein and uses thereof |
| WO2018011353A1 (en) * | 2016-07-14 | 2018-01-18 | Bioarctic Ab | Brain delivery protein |
| KR102550991B1 (ko) | 2016-07-18 | 2023-07-04 | 더 유니버시티 오브 브리티쉬 콜롬비아 | 아밀로이드 베타에 대한 항체 |
| US20180125920A1 (en) | 2016-11-09 | 2018-05-10 | The University Of British Columbia | Methods for preventing and treating A-beta oligomer-associated and/or -induced diseases and conditions |
| MX2019005594A (es) | 2016-11-15 | 2019-07-04 | H Lundbeck As | Agentes, usos y metodos para el tratamiento de la sinucleinopatia. |
| MA47019A (fr) | 2016-12-16 | 2021-04-21 | H Lundbeck As | Agents, utilisations et procédés |
| US10364286B2 (en) * | 2016-12-22 | 2019-07-30 | H. Lundbeck A/S | Monoclonal anti-alpha-synuclein antibodies for preventing tau aggregation |
| EP3567054A4 (en) * | 2017-01-06 | 2021-03-10 | ABL Bio Inc. | ANTI-ALPHA SYN ANTIBODIES AND USES THEREOF |
| US12049493B2 (en) | 2017-01-06 | 2024-07-30 | Abl Bio Inc. | Anti-alpha-synuclein antibodies and uses thereof |
| KR102573778B1 (ko) | 2017-02-17 | 2023-08-31 | 브리스톨-마이어스 스큅 컴퍼니 | 알파-시뉴클레인에 대한 항체 및 그의 용도 |
| KR20200015477A (ko) * | 2017-04-21 | 2020-02-12 | 임플리싯 바이오사이언스 피티와이 엘티디 | 신경 퇴행성 질환을 치료하기 위한 cd14 길항제 항체 |
| US11220538B2 (en) | 2017-05-01 | 2022-01-11 | The Trustees Of The University Of Pennsylvania | Monoclonal antibodies against alpha-synuclein fibrils |
| KR20200007945A (ko) | 2017-05-16 | 2020-01-22 | 암프리온, 인코퍼레이티드 | 미스폴딩된 타우 단백질의 검출 |
| KR20200033880A (ko) | 2017-08-02 | 2020-03-30 | 스트레스마크 바이오사이언시즈 인코퍼레이티드 | 항체 결합 활성 알파 시누클레인 |
| US11155608B2 (en) | 2017-08-23 | 2021-10-26 | The Trustees Of The University Of Pennsylvania | Monoclonal antibodies against pathological alpha-synuclein, and methods using same |
| RU2657763C1 (ru) * | 2017-09-12 | 2018-06-15 | федеральное государственное бюджетное образовательное учреждение высшего образования "Первый Санкт-Петербургский государственный медицинский университет имени академика И.П. Павлова" Министерства здравоохранения Российской Федерации | Способ диагностики болезни паркинсона |
| CA3082559A1 (en) * | 2017-11-17 | 2019-05-23 | Abl Bio Inc. | Antibodies to .alpha.-synuclein and uses thereof |
| BR112020011875A2 (pt) | 2017-12-14 | 2020-11-24 | Abl Bio Inc. | anticorpo biespecífico ao a-syn/igf1r e uso do mesmo |
| GB201720970D0 (en) * | 2017-12-15 | 2018-01-31 | Ucb Biopharma Sprl | Antibodies |
| GB201720975D0 (en) * | 2017-12-15 | 2018-01-31 | Ucb Biopharma Sprl | Anti-alpha synuclein antibodies |
| ES2955992T3 (es) | 2017-12-19 | 2023-12-11 | Chase Therapeutics Corp | Método para evaluar una sinucleinopatía |
| JP7498663B2 (ja) * | 2017-12-21 | 2024-06-12 | ハー・ルンドベック・アクチエゼルスカベット | アルファ－シヌクレイン病のアッセイ、方法、及び治療 |
| CN109957547A (zh) * | 2017-12-25 | 2019-07-02 | 深圳宾德生物技术有限公司 | 一种靶向cd317的嵌合抗原受体t细胞及其制备方法和应用 |
| CN109957546A (zh) * | 2017-12-25 | 2019-07-02 | 深圳宾德生物技术有限公司 | 一种靶向cd317的嵌合抗原受体t细胞及其制备方法和应用 |
| EP3773692A4 (en) * | 2018-04-04 | 2022-03-16 | University of Florida Research Foundation, Inc. | SUBSTANCES AND METHODS FOR THE TREATMENT OF LEWY BODY DISORDERS |
| TW202003576A (zh) * | 2018-05-10 | 2020-01-16 | 美商艾博視訊有限公司 | 活化cd40之單株抗體及其用途 |
| WO2020009482A1 (ko) * | 2018-07-03 | 2020-01-09 | 에이비엘바이오 주식회사 | 항 알파-시누클레인 항체 및 그 용도 |
| BR112021001272A2 (pt) | 2018-07-24 | 2021-04-27 | Eisai R&D Management Co., Ltd. | métodos de tratamento e prevenção de doença de alzheimer |
| BR112021006123A2 (pt) * | 2018-10-19 | 2021-07-20 | Janssen Vaccines & Prevention B.V. | anticorpos anti-sinucleína |
| JP7196311B2 (ja) * | 2018-12-12 | 2022-12-26 | ウーシー バイオロジクス アイルランド リミテッド | 抗ｔｉｍ－３抗体とその利用 |
| RU2703430C1 (ru) * | 2018-12-13 | 2019-10-16 | Федеральное государственное бюджетное учреждение "Национальный медицинский исследовательский центр глазных болезней имени Гельмгольца" Министерства здравоохранения Российской Федерации (ФГБУ "НМИЦ ГБ им. Гельмгольца" Минздрава России) | Способ прогнозирования развития нейродегенеративных заболеваний, в основе патогенеза которых лежит гамма-синуклеинопатия |
| TWI734279B (zh) * | 2018-12-14 | 2021-07-21 | 美商美國禮來大藥廠 | 抗α-突觸核蛋白抗體及其用途 |
| CN113727701B (zh) * | 2019-03-28 | 2023-11-28 | 香港中文大学 | 用于治疗神经变性疾病的sumo肽 |
| CA3136679A1 (en) | 2019-04-30 | 2020-11-05 | Chase Therapeutics Corporation | Alpha-synuclein assays |
| US20220291240A1 (en) * | 2019-08-27 | 2022-09-15 | The Johns Hopkins University | Biomarkers for neurodegenerative disorders |
| IL294408A (en) | 2019-12-31 | 2022-08-01 | Chase Therapeutics Corp | Kinases as biomarkers for neurodegenerative conditions |
| CN111171152B (zh) * | 2020-01-15 | 2023-04-18 | 吉林医药学院 | Pcsk9抗体及其制备方法和应用 |
| NL2025332B1 (en) * | 2020-04-10 | 2021-10-26 | Syngle Therapeutics B V | Novel alpha-synuclein binding antibodies, or antigen binding portions thereof. |
| EP4157875A1 (en) | 2020-06-02 | 2023-04-05 | Arcus Biosciences, Inc. | Antibodies to tigit |
| KR20230027095A (ko) | 2020-06-26 | 2023-02-27 | 바이오악틱 에이비 | α-시누클레인 프로토피브릴 결합 항체 |
| AU2022307687A1 (en) | 2021-07-09 | 2024-01-04 | Eisai R&D Management Co., Ltd. | Biomarkers for alzheimer's disease treatment |
| CA3230148A1 (en) | 2021-08-30 | 2023-03-09 | Eisai R&D Management Co., Ltd. | Subcutaneous formulations of anti-abeta protofibril antibody and methods of use thereof |
| AU2022439338A1 (en) | 2022-02-02 | 2024-08-15 | Eisai R&D Management Co., Ltd. | Methods of treatment using p-tau181 level |
| CN116589567B (zh) * | 2022-11-30 | 2024-03-19 | 西南大学 | 马铃薯x病毒单克隆抗体pvx-2及其应用 |
Family Cites Families (19)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR9911291A (pt) | 1998-07-03 | 2001-12-04 | Innogenetics Nv | Diagnóstico diferencial de neurodegeneração |
| UA81216C2 (en) | 1999-06-01 | 2007-12-25 | Prevention and treatment of amyloid disease | |
| AU2001268005A1 (en) | 2000-07-07 | 2002-01-21 | Lars Lannfelt | Prevention and treatment of alzheimer's disease |
| US20060018918A1 (en) | 2000-12-27 | 2006-01-26 | Board Of Regents, The University Of Texas System | Production of stabilized conformational isomers of disease associated proteins |
| TW200509968A (en) * | 2002-11-01 | 2005-03-16 | Elan Pharm Inc | Prevention and treatment of synucleinopathic disease |
| US8506959B2 (en) | 2002-11-01 | 2013-08-13 | Neotope Biosciences Limited | Prevention and treatment of synucleinopathic and amyloidogenic disease |
| US20080014194A1 (en) | 2003-10-31 | 2008-01-17 | Elan Pharmaceuticals, Inc. | Prevention and Treatment of Synucleinopathic and Amyloidogenic Disease |
| US7358331B2 (en) | 2003-05-19 | 2008-04-15 | Elan Pharmaceuticals, Inc. | Truncated fragments of alpha-synuclein in Lewy body disease |
| JP4931597B2 (ja) * | 2003-11-07 | 2012-05-16 | イミュネックス・コーポレーション | インターロイキン−４受容体を結合する抗体 |
| WO2005047860A2 (en) | 2003-11-08 | 2005-05-26 | Elan Pharmaceuticals, Inc. | Antibodies to alpha-synuclein |
| US20050203010A1 (en) | 2003-11-14 | 2005-09-15 | Atgen Co., Ltd. | Novel peptides conferring environmental stress resistance and fusion proteins including said peptides |
| SE0401601D0 (sv) | 2004-06-21 | 2004-06-21 | Bioarctic Neuroscience Ab | Protofibril specific antibodies and uses thereof |
| EP1989330A4 (en) | 2006-01-31 | 2009-10-21 | Elan Pharm Inc | ALPHA-SYNUCLEINE KINASE |
| ATE492561T1 (de) | 2006-03-23 | 2011-01-15 | Bioartic Neuroscience Ab | Verbesserte protofibrilselektive antikörper und deren verwendung |
| US8147833B2 (en) | 2007-02-23 | 2012-04-03 | Neotope Biosciences Limited | Prevention and treatment of synucleinopathic and amyloidogenic disease |
| CN101161245B (zh) * | 2007-11-29 | 2011-11-09 | 首都医科大学宣武医院 | 二苯乙烯苷及其衍生物抑制突触核蛋白过度表达的用途 |
| PT2282758T (pt) * | 2008-04-29 | 2019-02-12 | Bioarctic Ab | Anticorpos e vacinas para uso em métodos terapêuticos e diagnósticos para perturbações relacionadas com a alfa-sinucleína |
| ES2864049T3 (es) | 2009-06-29 | 2021-10-13 | Bioarctic Ab | Anticuerpos selectivos para protofibrillas/oligómeros de amiloide-P truncado en el extremo N |
| JP5894939B2 (ja) | 2010-02-26 | 2016-03-30 | バイオアークティック ニューロサイエンス アーベー | プロトフィブリル結合抗体ならびにパーキンソン病、レビー小体型認知症および他のα−シヌクレイノパチーの治療および診断方法におけるこれらの使用 |
-
2011
- 2011-02-25 JP JP2012554464A patent/JP5894939B2/ja active Active
- 2011-02-25 PL PL11713058T patent/PL2539366T3/pl unknown
- 2011-02-25 EP EP11713058.3A patent/EP2539366B1/en active Active
- 2011-02-25 SI SI201131419T patent/SI2539366T1/en unknown
- 2011-02-25 DK DK11713058.3T patent/DK2539366T3/en active
- 2011-02-25 WO PCT/IB2011/050826 patent/WO2011104696A1/en active Application Filing
- 2011-02-25 CN CN201180011363.XA patent/CN102869680B/zh active Active
- 2011-02-25 PT PT117130583T patent/PT2539366T/pt unknown
- 2011-02-25 CA CA2789963A patent/CA2789963C/en active Active
- 2011-02-25 CN CN201610801424.7A patent/CN106397588B/zh active Active
- 2011-02-25 CN CN201910950804.0A patent/CN110655573B/zh active Active
- 2011-02-25 RS RS20180129A patent/RS57029B1/sr unknown
- 2011-02-25 US US13/578,710 patent/US8632776B2/en active Active
- 2011-02-25 AU AU2011219414A patent/AU2011219414B2/en active Active
- 2011-02-25 RU RU2012140954/10A patent/RU2555526C2/ru active
- 2011-02-25 NO NO11713058A patent/NO2539366T3/no unknown
- 2011-02-25 ES ES11713058.3T patent/ES2661925T3/es active Active
- 2011-02-25 HU HUE11713058A patent/HUE038313T2/hu unknown
- 2011-02-25 LT LTEP11713058.3T patent/LT2539366T/lt unknown
-
2013
- 2013-08-01 US US13/957,239 patent/US8859501B2/en active Active
-
2014
- 2014-08-28 US US14/472,036 patent/US8968734B2/en active Active
-
2015
- 2015-02-02 US US14/611,690 patent/US9084832B2/en active Active
-
2018
- 2018-02-05 CY CY20181100140T patent/CY1120014T1/el unknown
- 2018-02-07 HR HRP20180230TT patent/HRP20180230T8/hr unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20180230T8 (hr) | Protutijela koja se vežu na protofibrile i njihova upotreba u terapijskim i dijagnostičkim postupcima kod parkinsonove bolesti, demencije s lewyjevim tijelima i drugih alfa-sinukleinopatija | |
| HRP20190092T1 (hr) | Antitijela i cjepiva za uporabu u terapijskim i dijagonstičkim postupcima za poremećaje vezane uz alfa-sinuklein | |
| HK1258817A1 (zh) | 合成三萜類化合物及用以治病之方法 | |
| PT3042910T (pt) | 2'-espiro-nucleósidos para utilização na terapia da hepatite c | |
| ZA201300100B (en) | Indolizine derivatives,process for the preparation thereof and therapeutic use thereof | |
| IL221160A (en) | 4,2,1-triazine-3-amine derivatives, a process for their preparation and use for drug preparation | |
| RS55927B1 (sr) | Fenil-3-aza-biciklo[3.1.0]heks-3-il-metanoni i njihova primena kao lek | |
| GB201105137D0 (en) | Therapeutic molecules for use in the suppression of Parkinson's disease | |
| IL217293A0 (en) | NOVEL 1,2,3,4 - TETRAHYDROPYRIMIDO {1,2-a} PYRIMIDIN - 6 - ONE DERIVATIVES, PREPARATION THEREOF AND PHARMACEUTICAL USE THEREOF | |
| IL217209A0 (en) | Novel antibodies and their uses in therapeutic and diagnostic methods | |
| PT2603238E (pt) | Métodos e composições farmacêuticas para o tratamento de uma doença ocular num indíviduo | |
| EP2528939A4 (en) | RECOMBINANT PROTEINS FOR USE IN VACCINES, ANTIBODIES TO THESE PROTEINS, AND DIAGNOSTIC AND THERAPEUTIC PROCEDURES THEREWITH | |
| EP2660600A4 (en) | DIAGNOSTIC MEDICINE AND DIAGNOSTIC METHOD FOR ALZHEIMER'S DISEASE | |
| PT2670769T (pt) | R2r1/2 em diagnóstico e terapêutica | |
| EP2731952A4 (en) | RADIOACTIVELY MARKED REDENDER DERIVATIVES AND THEIR USE IN SPECT IMAGING | |
| EP2348865A4 (en) | BETA-HYDROXY-GAMMA-AMINOPHOSPHONATES, THEIR METHODS OF PREPARATION AND THEIR USE |